Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease — Stella

Home/Chronic Kidney Diseases/Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

View on ClinicalTrials.gov

Recruiting

Back to Chronic Kidney Diseases trials

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Duke Research at Pickett Road, Durham, North Carolina

Key details

Phase

Safety & dosing

Sponsor

Duke University

Collaborators

National Institute on Minority Health and Health Disparities (NIMHD), Eli Lilly and Company

Enrollment target

~75 participants

Started

April 2023

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.